Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Lexeo Therapeutics (LXEO) Equity Average (2022 - 2026)

Lexeo Therapeutics' Equity Average history spans 2 years, with the latest figure at -$24.6 million for Q4 2023.

  • On a quarterly basis, Equity Average rose 76.75% to -$24.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$24.6 million, a 76.75% increase, with the full-year FY2023 number at $290500.0, changed N/A from a year prior.
  • Equity Average hit -$24.6 million in Q4 2023 for Lexeo Therapeutics, up from -$153.2 million in the prior quarter.
  • Over the last five years, Equity Average for LXEO hit a ceiling of -$24.6 million in Q4 2023 and a floor of -$153.2 million in Q3 2023.